Gene editors steady despite latest leadership shake-up at FDA
Source: SeekingAlpha
2025-06-20 08:39:22 ET
More on Editas Medicine
- Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
- Editas Medicine: Do The Risks Outweigh The Rewards?
- RFK Jr. looks to fast track rare disease drug approvals (updated)
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Seeking Alpha’s Quant Rating on Editas Medicine
Read the full article on Seeking Alpha
For further details see:
Gene editors steady despite latest leadership shake-up at FDA
Roche Holding Ltd ADR
NASDAQ: RHHBY
RHHBY Trading
-2.37% G/L:
$50.70 Last:
1,323,065 Volume:
$51.31 Open:
RHHBY Latest News
March 09, 2026 02:10:00 am
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
RHHBY Stock Data
$361,973,933,704
6,306,832,002
N/A
43
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
